


U.S. PHARMACOPEIA

Search USP29

Go

Paclitaxel



$C_{47}H_{51}NO_{14}$ 853.91

Benzenepropanoic acid, β -(benzoylamino)- α -hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1*H*-cyclodeca[3,4]benz[1,2-*b*]oxet-9-yl ester, [2a*R*]-[2a α ,4 β ,4a β ,6 β ,9 α (α *R**, β *S**)],11 α ,12 α ,12a α ,12b α]]-(2a*R*,4*S*,4a*S*,6*R*,9*S*,11*S*,12*S*,12a*R*,12b*S*)-1,2a,3,4,4a,6,9,10,11,12,12a,12b-Dodecahydro-4,6,9,11,12,12b-hexahydroxy-4a,8,13,13-tetramethyl-7,11-methano-5*H*-cyclodeca[3,4]-benz[1,2-*b*]oxet-5-one 6,12b-diacetate, 12-benzoate, 9-ester with (2*R*,3*S*)-*N*-benzoyl-3-phenylisoserine [33069-62-4].

» Paclitaxel contains not less than 97.0 percent and not more than 102.0 percent of $C_{47}H_{51}NO_{14}$, calculated on the anhydrous, solvent-free basis.

Abraxis EX2051
Actavis LLC v. Abraxis Bioscience, LLC
IPR2017-01101; IPR2017-01103; IPR2017-01104
Page 1 of 7

Caution—Paclitaxel is cytotoxic. Great care should be taken to prevent inhaling particles of Paclitaxel and exposing the skin to it.

Packaging and storage— Preserve in tight, light-resistant containers, and store at controlled room temperature.

Labeling— The labeling indicates the type of process used to produce the material and the *Related compounds* test with which the material complies.

USP Reference standards [〈 11 〉](#) — [USP Endotoxin RS.](#) [USP Paclitaxel RS.](#) [USP Paclitaxel Related Compound A RS.](#) [USP Paclitaxel Related Compound B RS.](#)

Identification—

A: [Infrared Absorption](#) [〈 197K 〉](#).

B: The retention time of the major peak in the chromatogram of the *Assay preparation* corresponds to that in the chromatogram of the *Standard preparation*, as obtained in the *Assay*.

Specific rotation [〈 781S 〉](#): between -49.0° and -55.0° at 20° , calculated on the anhydrous, solvent-free basis.

Test solution: 10 mg per mL, in methanol.

Microbial limits [〈 61 〉](#) — The total aerobic microbial count does not exceed 100 cfu per g. It meets the requirements of the tests for the absence of *Staphylococcus aureus*, *Pseudomonas aeruginosa*, *Salmonella* species, and *Escherichia coli*.

Bacterial endotoxins [〈 85 〉](#) — It contains not more than 0.4 USP Endotoxin Unit per mg of paclitaxel.

Water, Method Ic [〈 921 〉](#): not more than 4.0%.

Residue on ignition [〈 281 〉](#): not more than 0.2%.

Heavy metals, Method II [〈 231 〉](#): 0.002%.

Related compounds—

TEST 1 (*for material labeled as isolated from natural sources*)— If the material complies with this test, the labeling indicates that it meets *USP Related compounds Test 1*.

Diluent— Prepare as directed in the *Assay*.

Solution A— Prepare filtered and degassed acetonitrile.

Solution B— Prepare filtered and degassed water.

Mobile phase— Use variable mixtures of *Solution A* and *Solution B* as directed for *Chromatographic system*. Make adjustments if necessary (see *System Suitability* under [Chromatography](#) [〈 621 〉](#)).

System suitability solution— Dissolve accurately weighed quantities of [USP Paclitaxel Related Compound A RS](#) and [USP Paclitaxel Related Compound B RS](#) in methanol to obtain a solution having known concentrations of about 10 µg of each per mL. Transfer 5.0 mL of this solution to a 50-mL volumetric flask, dilute with *Diluent* to volume, and mix.

Standard solution— Dissolve, with the aid of sonication, an accurately weighed quantity of [USP Paclitaxel RS](#) in *Diluent*, and dilute quantitatively, and stepwise if necessary, with *Diluent* to obtain a solution having a known concentration of about 5 µg per mL.

Test solution— Use the *Assay preparation*.

Chromatographic system (see [Chromatography](#) (621))— The liquid chromatograph is equipped with a 227-nm detector and a 4.6-mm × 25-cm column that contains 5-µm packing L43. The flow rate is about 2.6 mL per minute. The column temperature is maintained at 30°. The chromatograph is programmed as follows.

Time (minutes)	Solution A (%)	Solution B (%)	Elution
0–35	35	65	isocratic
35–60	35→80	65→20	linear gradient
60–70	80→35	20→65	linear gradient
70–80	35	65	isocratic

Chromatograph the *System suitability solution*, and record the peak responses as directed for *Procedure*: the relative retention times are about 0.78 for paclitaxel related compound A and 0.86 for paclitaxel related compound B (relative to the retention time for paclitaxel obtained from the *Test solution*); and the resolution, *R*, between paclitaxel related compound A and paclitaxel related compound B is not less than 1.0. Chromatograph the *Standard solution*, and record the peak responses as directed for *Procedure*: the relative standard deviation for replicate injections is not more than 2.0%.

Procedure— Inject a volume (about 15 µL) of the *Test solution* into the chromatograph, record the chromatogram, and measure the areas for the major peaks. Calculate the percentage of each impurity in the portion of Paclitaxel taken by the formula:

$$100(Fr_i / r_U),$$

in which *F* is the relative response factor for each impurity peak (see [Table 1](#) for values); *r_i* is the peak area for each individual impurity; and *r_U* is the peak area for paclitaxel.

Table 1

Relative Retention Time	Relative Response Factor (<i>F</i>)	Name	Limit (%)
0.24	1.29	Baccatin III	0.2
0.53	1.00	10-Deacetylpaclitaxel	0.5
0.57	1.00	7-Xylosylpaclitaxel	0.2
0.78	1.26	Cephalomannine (paclitaxel related compound A)	a ₁ ¹

Relative Retention Time	Relative Response Factor (F)	Name	Limit (%)
0.78	1.26	2'',3''-Dihydrocephalomannine	a ₂ ¹
0.86	1.00	10-Deacetyl-7-epipaclitaxel (paclitaxel related compound B)	0.5
1.10	1.00	Benzyl analog ³	b ₁ ²
1.10	1.00	3'',4''-Dehydropaclitaxel C	b ₂ ²
1.40	1.00	7-Epicephalomannine	0.3
1.85	1.00	7-Epipaclitaxel	0.5

¹ Resolution may be incomplete for these peaks, depending upon the relative amounts present; the sum of a₁ and a₂ is not more than 0.5%.

² Resolution may be incomplete for these peaks depending upon the relative amounts present; the sum of b₁ and b₂ is not more than 0.5%.

³ The following chemical name is assigned to the related compound, benzyl analog: Baccatin III 13-ester with (2R,3S)-2-hydroxy-3-phenyl-3-(2-phenylacetylamino)propanoic acid.

In addition to not exceeding the limits for paclitaxel related impurities in [Table 1](#), not more than 0.1% of any other single impurity is found; and not more than 2.0% of total impurities is found.

TEST 2 (for material labeled as produced by a semisynthetic process)— If the material complies with this test, the labeling indicates that it meets *USP Related compounds Test 2*.

Diluent— Use acetonitrile.

Solution A— Use a filtered and degassed mixture of water and acetonitrile (3:2).

Solution B— Use filtered and degassed acetonitrile.

Mobile phase— Use variable mixtures of *Solution A* and *Solution B* as directed for *Chromatographic system*. Make adjustments if necessary (see *System Suitability* under [Chromatography](#) (621)).

System suitability solution— Dissolve accurately weighed quantities of *USP Paclitaxel RS* and *USP Paclitaxel Related Compound B RS* in *Diluent*, using shaking and sonication if necessary, to obtain a solution having known concentrations of about 0.96 mg and 0.008 mg per mL, respectively.

Test solution— Transfer about 10 mg of Paclitaxel, accurately weighed, to a 10-mL volumetric flask; dissolve in and dilute with *Diluent* to volume, using shaking and sonication if necessary; and mix.

Chromatographic system (see [Chromatography](#), § 621) — The liquid chromatograph is equipped with a 227-nm detector and a 4.6-mm × 15-cm column that contains 3- μ m packing L1. The flow rate is about 1.2 mL per minute. The column temperature is maintained at 35°. The chromatograph is programmed as follows.

Time (minutes)	Solution A (%)	Solution B (%)	Elution
0–20	100	0	isocratic
20–60	100→10	0→90	linear gradient
60–62	10→100	90→0	linear gradient
62–70	100	0	isocratic

Chromatograph the *System suitability solution*, and record the peak responses as directed for *Procedure*: the relative retention times are about 0.94 for paclitaxel related compound B and 1.0 for paclitaxel; the resolution, R , between paclitaxel related compound B and paclitaxel is not less than 1.2; and the relative standard deviation for replicate injections is not more than 2.0%.

Procedure— Separately inject equal volumes (about 15 μ L) of the *Diluent* and the *Test solution* into the chromatograph, record the chromatograms, and measure the areas for all the peaks. Disregard any peaks due to the *Diluent*. Calculate the percentage of each impurity in the portion of Paclitaxel taken by the formula:

$$100(F_i / r_s),$$

in which F is the relative response factor for each impurity (see [Table 2](#) for values); r_i is the peak area for each impurity obtained from the *Test solution*; and r_s is the sum of the areas of all the peaks obtained from the *Test solution*.

Table 2

Relative Retention Time	Relative Response factor (F)	Name	Limit (%)
0.11	1.24	10-Deacetylbaaccatin III	0.1
0.20	1.29	Baccatin III	0.2
0.42	1.39	Photodegradant ²	0.1
0.47	1.00	10-Deacetylpaclitaxel	0.5
0.80	1.00	2-Debenzoypaclitaxel-2-pentenoate	0.7
0.92 ¹	1.00	Oxetane ring opened, acetyl and benzoyl ²	x_1
0.92 ¹	1.00	10-Acetoacetylpaclitaxel	x_2
0.94 ¹	1.00	10-Deacetyl-7-epipaclitaxel (paclitaxel related compound B)	x_3
1.37	1.00	7-Epipaclitaxel	0.4
1.45	1.00	10,13-Bissidechainpaclitaxel ²	0.5
1.54	1.00	7-Acetylpaclitaxel	0.6

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.